LB

Lexington Blood

General Partner | Hedge Fund | VC | Fintech | Biotech

Park City, Utah

Invests in

  • Min Investment:

    $100,000.00
  • Max Investment:

    $5,000,000.00
  • Target Investment:

    $1,500,000.00

Work Experience

2023

  • Advisor

    2024

  • Cofounder

    2023 - 2024

    Upgrading Financial Institution's Assets Fintech company leveraging financial engineering through an end-to-end automated platform that unlocks value embedded in portfolios. Takara's first product measurably improves the profitability of Banks and Credit Unions lending portfolio by liquidating the gap between face value and market value on low fixed-rate mortgages. Our first-to-market solution upgrades assets into high-yield, lower-risk securities generating substantial profits without any loss recognition. *Meets all regulatory compliance laws for financial institutions.

  • General Partner

    2017

    Hedge Fund: Discretionary short equities, Quantitative investment management, automated algorithmic trading. Futures - S&P500, T-Notes, Oil, Commodities, Currencies, Bonds, Equities, HFT, Long Short, Global Markets 2014 - present. *Private

2018

  • Venture Partner

    2018

    Connecting and Underpinning the Digital Economy We are a global venture capital fund primarily focused on powering the digital economy through Artificial Intelligence, FinTech, and Digitization. Our mission is to leverage the power of capital and our deep network to back stellar teams solving the hardest problems, profitably. Fund IV USA and Fund V Saudi Arabia are now live actively fundraising and investing. Thesis: Demonstrable Traction. https://7bc.vc

  • Senior Financial Advisor

    2022

    Family Office of His Highness Sheikh Ahmed a UAE royal family member and diplomat currently invested in a variety of industries in public and private partnerships with governments in over 27 countries and counting around the globe.

2024

  • Board Advisor

    2024

  • Advisor

    2023

    SiliconMint provides dedicated software teams that architect, build and support mission-critical systems. We set ourselves apart by the technical depth and breadth of our engineering staff. With offices in San Francisco, New York, and Europe, we deliver innovative solutions worldwide. WHAT WE SPECIALIZE IN: ∙ Custom software development (.NET, Java, C#, C++, React, Angular, Vue.js, Node.js, React Native, Python, Go, etc.) ∙ Embedded Systems & IoT ∙ AI, ML, Cognitive Computing and Computer Vision development ∙ Science-intensive software development ∙ Software project rescue ∙ Enterprise legacy systems migration, and much more. The power to create full-fledged applications is now in the hands of everyone with a spreadsheet. Create software at 7 - 10X the speed. See it in action: https://mintdata.com/intro - Create any user interface (UI) with the ease of Sketch / PowerPoint - Create logic with the familiarity of a spreadsheet - Construct visual flows to connect with external & internal company data - Publish resulting applications to mobile devices and the desktop web - Run on-premise / your cloud or the MintData cloud Customers we’ve helped in the past: * Verizon: scalable IoT cloud with real-time analytics for millions of households; * Yahoo Japan: 16x improvement in ad approval process. Want to see a demo? https://mintdata.com/showcase

2023

  • Board Advisor

    2023

    ZOTH brings Global Defi liquidity to solve the $5 Trillion Credit gap in emerging markets for SME's & Startups while providing market beating fixed income for its investors Part of Foundership Accelerator Top 5 Defi Project in Hypernest by Polygon Part of Stellar Bootcamp Backed by Graviton, SOSV & Super Angels.

  • Cofounder

    2020

    In silico discovery, synthesis, and validation of custom macromolecules to modify protein-protein interactions. https://www.joinerybio.com/ 1- Discover/Design 2- Screen/Validate 3- Manufacture We are a service provider for companies trying to develop diagnostics and therapeutics. We offer high-throughput surface plasmon resonance (SPR) to quickly and cheaply screen massive amounts of antibodies and other protein-protein interactions. Alternatively, we have developed a mature evolutionary algorithm to quickly design, screen, and optimize antibodies, aptamers, and other biosensors at a fraction of the cost of even high-throughput screening. We can also produce large volumes of antibodies and proteins. We use a proprietary generative approach to rationally design de novo peptides and ‘mini’ proteins. Our proprietary in silico approach makes discovery of novel aptamers and macrocycles cheap and quick, while yielding better products. The resulting candidate compounds are used in proprietary diagnostic devices and for drug discovery contract work with pharmaceutical companies. Some examples include development of PPI modulators for cancer, diabetes, autoimmune disorders, and infectious diseases. Drug candidates and functional diagnostic components usually take a long time and a lot of money to discover. Doing so requires screening hundreds-to-thousands of natural and artificial compounds, evaluating their desired characteristics, and making slight modifications before going back to the drawing board. The combinatorial space from which to choose compounds is around 10^50 candidates. Despite their potential as drug targets and in diagnostics, PPIs have yet to be precisely modified. Antibodies are most commonly engineered to bind undruggable PPIs. However, antibodies, aptamers, and macrocycles are not easy, quick, or cheap to discover.

  • Advisor

    2016

    Nano Engineered Circulatory Support Fluid (nano blood volume expander for septic shock, hemorrhagic shock and refractory shock trauma treatment) FDA clearance February 2019 for expedited 505b phase IIA clinical trials. VBI1-a refractory shock treatment planning clinical trials. VBI-S also cleared for expedited 505b phase IIA clinical trials in 2020 and completed early results in first 13 patients achieving 100% success to date. Received funding from the US Navy to complete the trials and EUA for right to life for Covid patients who end up with sepsis. https://www.prnewswire.com/news-releases/vivacelle-bio-receives-5-3-million-award-from-the-us-navy-for-a-clinical-trial-of-vbi-s-for-treatment-of-hypovolemia-of-septic-shock-due-to-covid-or-other-pathogens-301178451.html Robust IP with 25+ patents issued to date in the US, EU, India, Brazil, Mexico, Argentina, Canada. Applications: hypovolemic shock due to trauma or blood loss related injuries: sepsis, burns, chemical & biological warfare, acute radiation injury, spinal cord injury, fluid loss due to vomiting or diarrhea, ebola virus.

2020

  • Peace Fellow

    2020

    United Nations Educational, Scientific and Cultural Organization Since wars begin in the minds of men and women, it is in the minds of men and women that the defences of peace must be constructed. UNESCO Constitution WHAT IS UNESCO? UNESCO is the United Nations Educational, Scientific and Cultural Organization. It seeks to build peace through international cooperation in Education, the Sciences and Culture. UNESCO's programmes contribute to the achievement of the Sustainable Development Goals defined in Agenda 2030, adopted by the UN General Assembly in 2015.